Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C26444
http://purl.obolibrary.org/obo/NCIT_C26444
|
|---|---|
| Preferred Name | Golnerminogene Pradenovec |
| Definitions |
A recombinant agent consisting of a genetically-modified adenovirus 5 vector encoding the protein cytokine tumor necrosis factor (TNF) alpha. TNF exhibits potent anti-tumor cytolytic properties; the adenovirus 5 vector efficiently infects tumor cells, delivering tumor-specific TNF.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A recombinant agent consisting of a genetically-modified adenovirus 5 vector encoding the protein cytokine tumor necrosis factor (TNF) alpha. TNF exhibits potent anti-tumor cytolytic properties; the adenovirus 5 vector efficiently infects tumor cells, delivering tumor-specific TNF. |
|---|---|
| label | Golnerminogene Pradenovec
|
| prefLabel | Golnerminogene Pradenovec
|
| Legacy Concept Name | Adenovirus_5-Tumor_Necrosis_Factor_Alpha
|
| in_subset |
See more
See less
|
| Preferred_Name | Golnerminogene Pradenovec
|
| Is_Value_For_GDC_Property | |
| Display_Name | Golnerminogene Pradenovec
|
| Maps_To | Golnerminogene Pradenovec
|
| PDQ_Open_Trial_Search_ID | 258431
|
| UMLS_CUI | C1327819
|
| prefixIRI | NCIT:C26444
|
| Accepted_Therapeutic_Use_For | Treatment of solid tumors including pancreatic cancer
|
| NCI_Drug_Dictionary_ID | 258431
|
| Contributing_Source | CTRP
|
| subClassOf | |
| code | C26444
|
| type | |
| ALT_DEFINITION | A gene therapy product that is being studied in combination with radiation therapy in the treatment of cancer.
|
| PDQ_Closed_Trial_Search_ID | 258431
|
| Semantic_Type | Pharmacologic Substance
|
| CAS_Registry | 957472-14-9
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |